Top ▲
GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
MAP kinases (CMGC kinases) may be divided into three major families: ERK, JNK and p38 MAP kinases.
ERK may be activated by phosphorylation by the dual specificity mitogen-activated kinase kinases, MAP2K1 (Q02750, also known as MEK1) and MAP2K2 (P36507, also known as MEK2). The inhibitors PD98059 [1,3] and U0126 [4-5] act to inhibit these enzymes [2], and are used to inhibit ERK1 and ERK2.
JNK may be activated by phosphorylation by the dual specificity mitogen-activated kinase kinases, MAP2K4 (P45985, also known as JNKK1) and MAP2K7 (O14733, also known as JNKK2) .
p38 may be activated by phosphorylation by the dual specificity mitogen-activated kinase kinases, MAP2K3 (P46734, also known as MEK3) and MAP2K6 (P52564, also known as SAPKK3).
|
Families that contain targets of relevance to immunopharmacology are highlighted in blue |
|
|
|
Database page citation:
Mitogen-activated protein kinases (MAP kinases). Accessed on 08/04/2026. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=288.
Concise Guide to PHARMACOLOGY citation:
Alexander SPH, Fabbro D, Gibb AJ, Kelly E, Mathie AA, Peach CJ, Veale EL, Armstrong JF, Faccenda E, Harding SD, Southan C, Davies JA et al. (2025) The Concise Guide to PHARMACOLOGY 2025/26: Enzymes. Br J Pharmacol. 182: S307-S403.